Similar articles

• Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.

  Anné PR. Anné PR. Semin Oncol. 2002 Dec;29(6 Suppl 19):80-3. doi: 10.1053/sonc.2002.37350b. Semin Oncol. 2002. PMID: 12577250 Clinical Trial.
• [Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].

  Huang R, Yu H, Kuang A. Huang R, et al. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2002 Dec;19(4):708-11. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2002. PMID: 12561384 Review. Chinese.
• Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.

  Bourhis J, Rosine D. Bourhis J, et al. Semin Oncol. 2002 Dec;29(6 Suppl 19):61-2. doi: 10.1053/sonc.2002.37349. Semin Oncol. 2002. PMID: 12577247 Review.
• Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.

  Bardet E, Martin L, Calais G, Tuchais C, Bourhis J, Rhein B, Feham N, Alphonsi M. Bardet E, et al. Semin Oncol. 2002 Dec;29(6 Suppl 19):57-60. doi: 10.1053/sonc.2002.37348. Semin Oncol. 2002. PMID: 12577246 Clinical Trial.
• Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.

  Veerasarn V, Phromratanapongse P, Suntornpong N, Lorvidhaya V, Sukthomya V, Chitapanarux I, Tesavibul C, Swangsilpa T, Khorprasert C, Shotelersuk K, Kongthanarat Y, Panichevaluk A, Chiewvit S, Pusuwan P, Aekmahachai M, Ratchadara S, Sirilipoche S, Saengsuda Y. Veerasarn V, et al. J Med Assoc Thai. 2006 Dec;89(12):2056-67. J Med Assoc Thai. 2006. PMID: 17214057 Clinical Trial.